Literature DB >> 8721279

Determination of pefloxacin and its main active metabolite in human serum by high-performance liquid chromatography.

N Abanmi1, I Zaghloul, N El Sayed, K I Al-Khamis.   

Abstract

A high-performance liquid chromatographic (HPLC) method is described for the simultaneous determination of a fluoroquinolone, pefloxacin, and its main active metabolite norfloxacin (N-desmethyl metabolite) in serum. Sample preparation involves protein precipitation with acetonitrile. The drugs and the internal standard (acebutolol) were eluted from a 4-microns Novapak C-18 cartridge at ambient temperature with an isocratic mobile phase consisting of 14% acetonitrile in buffer solution, at a flow rate of 2.5 ml/min. The effluent was monitored on a fluorescence detector using excitation and emission wave-lengths of 330 and 440 nm, respectively. Each analysis required no longer than 8 min. Quantification was achieved by measurement of the peak-area ratio of the drugs to the internal standard, and the limit of quantification for both pefloxacin and norfloxacin in serum was 50 ng/ml. The intraday coefficient of variation (CV) ranged from 1.3 to 4.4% and from 2.2 to 7.5% for pefloxacin and norfloxacin, respectively, at the concentration ranges evaluated. The interday CV ranged from 1.1 to 5.9% and from 2.3 to 5.6% for pefloxacin and norfloxacin, respectively, at three concentrations. Relative recovery was 105.5 and 99.5% for pefloxacin and norfloxacin, respectively. Stability tests show that pefloxacin and norfloxacin are stable in serum for at least 3 weeks when stored at -20 degrees C. This method has been used successfully in pharmacokinetic studies in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8721279     DOI: 10.1097/00007691-199604000-00009

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  1 in total

1.  Pharmacokinetics of pefloxacin and its interaction with cyclosporin A, a P-glycoprotein modulator, in rat blood, brain and bile, using simultaneous microdialysis.

Authors:  T H Tsai
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.